Ndrepepa Gjin, Braun Siegmund, Mehilli Julinda, von Beckerath Nicolas, Nekolla Stephan, Vogt Wolfgang, Schwaiger Markus, Schömig Albert, Kastrati Adnan
Klinik für Herz- und Kreislauferkrankungen, Munich, Germany.
Am J Cardiol. 2006 Apr 15;97(8):1151-6. doi: 10.1016/j.amjcard.2005.11.029. Epub 2006 Mar 3.
We investigated whether N-terminal pro-brain natriuretic peptide (NT-pro-BNP) that was measured on admission in patients with acute myocardial infarction (AMI) predicts the efficacy of reperfusion or whether NT-pro-BNP provides prognostic information independent of infarct size as estimated by single-photon emission computed tomographic scintigraphy. The study included 174 patients with ST-segment elevation AMI who were admitted within 24 hours of pain onset. NT-pro-BNP level was measured on admission. Paired scintigraphic studies (before and 7 to 14 days after reperfusion) were performed to assess infarct size and define myocardial salvage. One-year clinical follow-up was assessed. Patients were categorized into the high NT-pro-BNP group (57 patients in the upper tertile of NT-pro-BNP) and low NT-pro-BNP group (117 patients in the middle and lower tertiles of NT-pro-BNP). Initial median perfusion defect was 35.0% (interquartile rage 20.0 to 53.0%) of the left ventricle in the high NT-pro-BNP group versus 19.0% (interquartile range 10.0 to 32.2) of the left ventricle in the low NT-pro-BNP group (p <0.001). Median salvage index was 0.36 (interquartile range 0.16 to 0.86) in the high NT-pro-BNP group versus 0.53 (interquartile range 0.31 to 0.75) in the low NT-pro-BNP group (p = 0.22). After adjustment in Cox's proportional hazards model, NT-pro-BNP remained an independent correlate of 1-year mortality (adjusted hazard ratio 2.31, 95% confidence interval 1.09 to 4.89, p = 0.03, high vs low NT-pro-BNP group). In conclusion, NT-pro-BNP measured on admission in patients with AMI correlates with scintigraphic area at risk and predicts prognosis but does not predict the efficacy of mechanical reperfusion by stenting or angioplasty.
我们研究了急性心肌梗死(AMI)患者入院时检测的N末端脑钠肽前体(NT-pro-BNP)是否能预测再灌注疗效,或者NT-pro-BNP是否能提供独立于单光子发射计算机断层扫描闪烁显像估计的梗死面积的预后信息。该研究纳入了174例ST段抬高型AMI患者,这些患者在疼痛发作24小时内入院。入院时检测NT-pro-BNP水平。进行了配对闪烁显像研究(再灌注前和再灌注后7至14天)以评估梗死面积并确定心肌挽救情况。进行了一年的临床随访评估。患者被分为高NT-pro-BNP组(NT-pro-BNP处于上三分位数的57例患者)和低NT-pro-BNP组(NT-pro-BNP处于中三分位数和下三分位数的117例患者)。高NT-pro-BNP组初始左心室灌注缺损中位数为35.0%(四分位数间距20.0%至53.0%),而低NT-pro-BNP组为19.0%(四分位数间距10.0%至32.2%)(p<0.001)。高NT-pro-BNP组挽救指数中位数为0.36(四分位数间距0.1